Special Seminar: Pharmaceutical Development in Infectious Diseases and Vaccines: Recent Successes and Failures
04/17/2008
Columbia Science and Technology Ventures (STV), along with the Columbia University Department of Biomedical Engineering and the Columbia Biotech Association, invite you to attend a special seminar
Pharmaceutical Development in Infectious Diseases and Vaccines: Recent Successes and Failures
Speaker: Dr. Keith Gottesdiener, Vice President, Clinical Infectious
Diseases and Vaccines, Merck Research Laboratories
Date: Thursday, April 17th, 2008
Time: 4 – 5:30 pm
Location: Columbia University Medical Center , 630 West 168 Street, P&S
Building 7th Floor, Room A-7
Vaccines and infectious diseases therapeutics (antibiotic, antifungal, antiviral, and antiparasitic drugs) have made an important mark on human health, and arguably have saved more human lives and prevented more human disease than any other class of therapeutic interventions. This seminar will introduce approaches to choosing vaccine and infectious diseases targets for development, outline translational methods that could speed registration of novel agents, and discuss challenges to clinical development and registration. In particular, a recent success (the new HPV vaccine) and a recent failure (the HIV vaccine STEP trial) will be presented.
Keith Gottesdiener, M.D., is vice president, Clinical Research, for Merck & Co., Inc. In this position he leads the Clinical Infectious Diseases and Vaccines area, responsible for the development of Merck's infectious diseases and vaccine products from early clinical studies, through late clinical development, registration, and life cycle management. He is responsible for more than 40 clinical programs and products, including Gardasil™ (HPV Vaccine), Rotateq™ (rotavirus vaccine), Zostavax™ (zoster vaccine) and Isentress™ (HIV integrase inhibitor), among others.
Dr. Gottesdiener joined Merck Research Labs as an associate director in early clinical development in 1995. In that role he helped transition compounds from the bench to the bedside and through to proof of concept. During the next 10 years at Merck, he held positions of increasing responsibility, eventually leading the early clinical development/clinical pharmacology department at Merck from 2001 through 2006, following which he was appointed to his current position.
Dr. Gottesdiener received his B.A. from Harvard College and his M.D. from the University of Pennsylvania . He completed his residency in internal medicine at the Brigham and Women's Hospital of Harvard Medical School. He also completed an infectious diseases fellowship at the combined Brigham and Women's Hospital-Beth Israel Medical Center-Dana Farber Cancer Institute Children’s Hospital program.
After his fellowship, Dr. Gottesdiener did post-doctoral research in the laboratory of Dr. Jack Strominger at Dana Farber Cancer Institute working on the molecular immunology of the T-cell receptor. In 1986, he joined the faculty as an assistant professor at Columbia University , and continued a research post-doc in the laboratory of Dr. Lex Van der Ploeg (Dept of Genetics and Development), working on gene transcriptional control in parasites. He started his independent laboratory at Columbia in 1991 with NIH RO-1 independent funding, focusing on gene transcription. In 1995, Dr. Gottesdiener was appointed Associate Clinical Professor of Medicine at Columbia University , and continued his association with Columbia while at Merck.
*Seats will be limited*, so please RSVP by replying to this message or sending an email to stvhelp@columbia.edu if you plan to attend. Faculty, post-docs, graduate students are encouraged to attend.
The Columbia Science and Technology Venture Lecture Series is designed to share perspectives from industry and venture capital with Columbia faculty and students, and to foster a spirit of entrepreneurship at Columbia.
Please visit our website at www.stv.columbia.edu for additional lecture topics and information about our office.